Investornewsbreaks VERAXA Biotech AG (NASDAQ: VRXA) Developing Next-Gen Cancer Therapies With Dual-Targeting Approach

(MENAFN- Investor Brand Network) VERAXA Biotech (NASDAQ: VRXA) is developing an oncology pipeline centered on engineered antibody therapies, with a particular focus on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting“AND-gated” approach intended to activate therapeutic effects preferentially when two tumor-associated targets are present on the same cancer cell, potentially addressing the challenge of on-target, off-tumor toxicity. The company has reported early laboratory data supporting the concept in both TCE and ADC applications, while its lead BiTAC-TCE has advanced into cell-line development and planned IND/CTA-enabling work following regulatory feedback from Germany's Paul-Ehrlich-Institute. Separately, VERAXA's VXA-222 bispecific ADC has progressed beyond antibody discovery following its collaboration with OmniAb.

To view the full article, visit

About VERAXA Biotech AG

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. For regular updates about VERAXA Biotech, visit .

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company's newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: /Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

MENAFN16092026000224011066ID1111676747